Stereotaxis ( (STXS) ) has released its Q4 earnings. Here is a breakdown of the information Stereotaxis presented to its investors.
Stereotaxis is a leading company in the field of surgical robotics, specializing in minimally invasive endovascular interventions. The company is recognized for its innovative robotic systems that enhance precision and safety in medical procedures.
In its latest earnings report, Stereotaxis highlighted a significant year-over-year revenue growth of 39% in the fourth quarter, driven by increased robotic system sales and the integration of Access Point Technologies. The company also achieved several regulatory milestones, including approvals in Europe and China, which are expected to bolster future growth.
Key financial metrics from the report include a fourth-quarter revenue of $6.3 million, with system revenue at $1.4 million and recurring revenue at $4.9 million. The company reported a gross margin of approximately 51% for the quarter and ended the year with $12.4 million in cash and no debt. Despite an operating loss of $7.6 million in the fourth quarter, Stereotaxis managed to generate positive cash flow, reflecting its strategic focus on sustainable growth.
Looking ahead, Stereotaxis anticipates continued double-digit revenue growth in 2025, supported by increasing catheter adoption and a robust system backlog. The company is poised to advance its product ecosystem and capitalize on new commercial opportunities, setting the stage for substantial growth in 2026.